ERT Launches Newly Designed Website
News Apr 20, 2009
ERT, a provider of centralized ECG and eClinical technology, ePRO and services to the biopharmaceutical, medical device and related industries, has announces the launch of its newly designed website at www.ERT.com following an extensive and successful company rebrand.
According to Company, the new and improved website provides an online experience detailing information on ERT’s portfolio of clinical trial solutions as well as all the latest company news and events, which serve to educate customers and facilitate inquiries.
Building on its long established pedigree and reputation in the industry, ERT has adopted an entirely new identity and brand image following extensive external and internal assessment. As a result the website has undergone a complete redesign that now enables users to navigate the site. The contemporary and intuitive design of the website underpins the recently launched brand strategy and new visual identity.
The new website is aimed at giving visitors a better understanding of ERT and its products and services. Comprehensive information is provided on the four new sub-brands of its products and services, including ERT Cardiac Safety Solutions, ERT EDC Solutions, ERT ePRO Solutions and ERT Clinical Research Consulting Group. A resource centre includes a white paper library and product demonstrations, while a separate news and events section provides users and media contacts with clear up-to-date information.
Michael McKelvey, President and CEO of ERT, said: “2009 is an exciting year for ERT as we continue to move forward in establishing the company as the most experienced and reliable partner in products and services for clinical trials. In line with our new brand strategy, we wanted to create a more engaging online experience for our customers and the new website reflects the dynamic new company image and the ERT commitment to quality, customer satisfaction and getting the job done right.”
An investigational drug for the treatment of sickle cell disease shows early promise in Phase 2a clinical trial. The orally administered drug, given to adult patients with sickle cell disease, is demonstrating tolerability and the ability to impact both red and white blood cell biomarkers of the disease.READ MORE
Researchers report that an experimental drug called vosoritide, allowed the average annual growth rate to increase in a study of 35 children and teenagers with a form of dwarfism. The average boost in height per year was ~6 centimeters (2.4 inches) which is close to growth rates among children of average stature.READ MORE